MARKET

RETA

Reata Pharmaceut
RETA
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-12.4710
277.82
74.73
6,566,444,250.68
UPDATE 1-Biogen beats quarterly profit estimates, Alzheimer's drug sales jump
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump. The company's shares up 4% before the bell. Biogen has cut jobs and abandoned controversial drug Aduhelm to boost growth. Company says its new drug Leqembi recorded global sales of about $19 million.
Reuters · 1d ago
Weekly Report: what happened at RETA last week (0226-0301)?
Weekly Report · 03/04 09:35
Weekly Report: what happened at RETA last week (0219-0223)?
Weekly Report · 02/26 09:38
Weekly Report: what happened at RETA last week (0212-0216)?
Weekly Report · 02/19 09:39
BUZZ-PREVIEW: Biogen shares rise; Q4 EPS, rev seen declining
Biogen shares up 1% ahead of quarterly report due out before market open on Tuesday. Q4 adj EPS, rev seen declining 3% y/y. Biogen warned of one-time charge of $60m for Alzheimer's treatment Aduhelm in Jan. Shares of Biogen down 5.6% in 2013.
Reuters · 02/12 20:53
Weekly Report: what happened at RETA last week (0205-0209)?
Weekly Report · 02/12 09:35
Weekly Report: what happened at RETA last week (0129-0202)?
Weekly Report · 02/05 09:38
Weekly Report: what happened at RETA last week (0122-0126)?
Weekly Report · 01/29 09:35
More

Webull offers Reata Pharmaceut stock information, including NASDAQ: RETA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RETA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RETA stock methods without spending real money on the virtual paper trading platform.